Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling
Karl S. Lang, … , Hans Hengartner, Rolf M. Zinkernagel
Karl S. Lang, … , Hans Hengartner, Rolf M. Zinkernagel
Published September 1, 2006
Citation Information: J Clin Invest. 2006;116(9):2456-2463. https://doi.org/10.1172/JCI28349.
View: Text | PDF
Research Article Autoimmunity

Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling

  • Text
  • PDF
Abstract

The liver is known to be a classical immunoprivileged site with a relatively high resistance against immune responses. Here we demonstrate that highly activated liver-specific effector CD8+ T cells alone were not sufficient to trigger immune destruction of the liver in mice. Only additional innate immune signals orchestrated by TLR3 provoked liver damage. While TLR3 activation did not directly alter liver-specific CD8+ T cell function, it induced IFN-α and TNF-α release. These cytokines generated expression of the chemokine CXCL9 in the liver, thereby enhancing CD8+ T cell infiltration and liver disease in mice. Thus, nonspecific activation of innate immunity can drastically enhance susceptibility to immune destruction of a solid organ.

Authors

Karl S. Lang, Panco Georgiev, Mike Recher, Alexander A. Navarini, Andreas Bergthaler, Mathias Heikenwalder, Nicola L. Harris, Tobias Junt, Bernhard Odermatt, Pierre-Alain Clavien, Hanspeter Pircher, Shizuo Akira, Hans Hengartner, Rolf M. Zinkernagel

×

Figure 2

No influence of TLR3 ligation on CD8+ T cell effector function.

Options: View larger image (or click on image) Download as PowerPoint

                  No influence of TLR3 ligation on CD8+
               ...
107 splenocytes from LCMV-gp33/H-2Db–specific TCR-Tg 318 mice were injected i.v. into naive C57BL/6 mice. Mice were immunized with gp33 (1 mg in PBS) and CpG on days 0 and 4. A separate group of mice was additionally treated with poly(I:C) on day 7. The phenotype and function of CD8+ T cells were analyzed 24 hours (A–E; n = 3 per group) or 12 hours (F; n = 2–3 per group) later. (A) Splenocytes were analyzed by FACS for early activation marker CD25 and CD69. Histogram plots show cells gated on CD8 and Thy1.1 (marker for 318 T cells). Gray shading indicates staining with isotype control antibody. Values for FACS analysis give mean fluorecence intensity (MFI). For other plots in A, B, and C, the number of positive expressing cells (marked by bar or quadrant) are given. (B) Splenocytes were further analyzed for surface expression of CD44, CD62L, IL-7Rα, and VLA-4 (CD49d). Histogram plots show cells gated for CD8 expression and tet-gp33 expression (indicated by a black line) or tet-gp33–negative cells (control expression, indicated by gray shading). (C) Splenocytes were restimulated in vitro with or without gp33, then analyzed for intracellular expression of granzyme B and IFN-γ. Dot plots show cells gated for CD8 expression. (D and E) Splenocytes were analyzed for their ability to lyse peptide-loaded target cells in vitro (D) or in vivo (E). Naive splenocytes served as negative control; splenocytes from mice infected with 2 × 106 pfu of LCMV-WE (WE high) served as positive control. (F) Eight hours after treatment with poly(I:C), splenocytes were analyzed for their expression of granzyme B (n = 2–3).

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts